Illumina may be at fair value after Genomics AI launch; stock up 191% in one year
FROM THE WIRE · FINANCE.YAHOO.COM
Illumina has delivered a striking share price run over the past year, and that kind of move naturally raises a question about whether the current valuation lines up with the cash the business is expected to generate. With the stock now trading at US$276.67, the issue is how much…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralIllumina's strong rally raises valuation questions; SpliceAI2 launch may support future cash flows but 50.7x P/E is elevated.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Illumina has surged 191.1% over the past year, with the stock now trading at US$276.67.
- 02The company launched SpliceAI2, an AI model that identified 17% more disease-relevant variants in a rare disease dataset.
- 03The 50.7x P/E suggests much of future growth is already priced into current market value.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets